Redeye views the Q4 report as a sizable top-line beat, exceeding forecasts by 110% despite the quarter being a seasonal low.
Redeye provides its initial take on Moberg Pharma’s Q4 report, where sales greatly exceeded our expectations.
Redeye views the Q3 report as solid, with sales slightly ahead of expectations and tighter cost control than anticipated.
Redeye comments on Moberg Pharma’s Q3 report, in which sales came in slightly ahead of our forecast at SEK4.
Redeye comments on the announcement that Moberg Pharma has signed an exclusive license agreement with Karo Healthcare for the commercialisat...
Q2 confirms that Moberg’s Terclara is now the market leader in both Sweden and Norway.
Moberg Pharma successfully launched Teclara in Sweden last year, and the early initial feedback from Norway based on April and May is powerf...
Q1 confirms that Terclara defends a leading market position in Sweden and that the Norwegian launch is well underway into the high season, e...
Q1 confirms that Moberg’s Terclara is the market leader in Sweden and that Terclara is on track for a Norwegian launch into the current high...
Redeye views the Q4 report as uneventful in many respects, as most of the events were communicated during the quarter.
Redeye comments on the Q4 report from Moberg Pharma.
Redeye comments on the ongoing launch in Norway of Terclara.
Redeye comments on a new additional supplier of Terbinafine that already holds an EU certificate of Suitability.
Redeye comments on the press release from Moberg Pharma last night.
Redeye views the Q3 report as relatively uneventful, apart from the apparent successful launch of Terclara in Sweden.
Redeye comments on the Q3 report from Moberg Pharma.
Redeye comments on the news about the company’s lower-than-expected number of patients who have achieved clinical cure in the blinded subset...
Redeye comments on the lowered expectations of the primary endpoint in the ongoing phase 3 trial.
Redeye views the Q2 report as further confirmation of a successful strategy to already arrive at being the Swedish market leader.
Redeye saw a report where sales exceeded our expectations.
Redeye comments on the outcome of the T02 and the directed issue to the top guarantors, which brought in a strong SEK 336m before costs.
Redeye comments on the news that Moberg Pharma has secured the exercise of warrants and entered into a top guarantee.
Redeye comments on the subscription price and the strong start of the Terclara launch.
Redeye views the Q1 report as a confirmation of the progress made with the first sales of Terclara in the books and processes proceeding as ...
Redeye saw a report where the first sales were reported for Terclara, and the cost aligned with expectations.
Redeye views the news from Moberg Pharma that they have submitted an additional Terbinafine supplier to the company’s registration dossier a...
Redeye sees the end-of-year report as results as uneventful.
Redeye saw a report that came in as expected regarding the results.
Redeye comments on the official launch of MOB-015 under the name Terclara in Sweden.
Redeye views the Q3 report from Moberg Pharma as very much in line with what was expected.
Redeye saw a report that came in more or less as expected.
Redeye is encouraged to learn that Moberg Pharma has completed the enrollment to the Phase 3 study for MOB-015 in North America.
Redeye briefly comments on the news about the outcome of the rights issue.
Redeye sees the approval in the Swedish market as the most important in the short perspective as the Swedish market is the first launch mark...
Redeye saw a report that was roughly in line with our expectations.
Redeye is encouraged by the news that Ireland is the first market to receive national approval for MOB-015 after the decentralized procedure...
Redeye was glad to see that Moberg Pharma received the EU approval within the indicated time frame.
Redeye comments on the EU approval of MOB-015 and the new two-step approach to the EU launch.
Redeye sees a relatively uneventful report with some positive highlights with continued progress in the EU regulatory process and the Phase ...
Redeye’s initial comment on the Q1 report was published earlier this morning.
Redeye sees no big drama in the termination of the license agreement with Taisho Pharmaceutical in Japan.
Redeye sees a Q4 report that was uneventful as expected.
Redeye’s initial comment on the Q4 report was published earlier this morning.
Redeye’s comments on the Q3 report that was published earlier this morning.
Redeye’s comments on the Q2 report that was published earlier this morning.
Redeye is positive about the work done by Moberg Pharma to further strengthen their partner network for MOB-015 and how it points to the str...
Redeye’s comments on the Q1 report that was published earlier this morning.
Redeye comments on this morning’s fully guaranteed rights issue.
Redeye views the submittal of the full application of the marketing authorization for MOB-015 as positive, although expected.
Redeye regards this morning’s news about the regulatory submission of the North American phase 3 study as very positive.
Redeye makes slight adjustments to the near-term estimates.
Redeye's initial comment on the Q2 report this morning.
